Insider Selling: Aadi Bioscience, Inc. (NASDAQ:AADI) Chairman Sells 15,415 Shares of Stock

Aadi Bioscience, Inc. (NASDAQ:AADI) Chairman Neil Desai sold 15,415 shares of Aadi Bioscience stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $1.50, for a total transaction of $23,122.50. Following the sale, the chairman now owns 1,236,128 shares in the company, valued at $1,854,192. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Neil Desai also recently made the following trade(s):

• On Monday, August 5th, Neil Desai sold 5,652 shares of Aadi Bioscience stock. The stock was sold at an average price of $1.34, for a total transaction of $7,573.68.
• On Monday, July 1st, Neil Desai sold 31,348 shares of Aadi Bioscience stock. The stock was sold at an average price of $1.45, for a total value of $45,454.60.

Aadi Bioscience Trading Down 3.6 %

Shares of NASDAQ AADI opened at $1.35 on Thursday. Aadi Bioscience, Inc. has a twelve month low of $1.28 and a twelve month high of $7.24. The firm has a 50-day moving average of $1.58 and a two-hundred day moving average of $1.82. The company has a market capitalization of $33.15 million, a price-to-earnings ratio of -0.53 and a beta of 0.69.

Aadi Bioscience (NASDAQ:AADI) last released its earnings results on Wednesday, May 8th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.02). Aadi Bioscience had a negative return on equity of 61.83% and a negative net margin of 288.72%. The business had revenue of $5.35 million during the quarter, compared to the consensus estimate of $6.41 million. As a group, research analysts predict that Aadi Bioscience, Inc. will post -2.54 earnings per share for the current year.

Institutional Trading of Aadi Bioscience

A number of hedge funds have recently bought and sold shares of AADI. Acuitas Investments LLC raised its holdings in shares of Aadi Bioscience by 10.8% during the second quarter. Acuitas Investments LLC now owns 352,483 shares of the company’s stock valued at $515,000 after acquiring an additional 34,344 shares during the period. Marquette Asset Management LLC purchased a new position in Aadi Bioscience during the 1st quarter worth approximately $135,000. Finally, Decheng Capital LLC purchased a new position in Aadi Bioscience during the 4th quarter worth approximately $1,063,000. 52.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating on shares of Aadi Bioscience in a research report on Tuesday, May 14th.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.